VLRX - Valeritas Holdings, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.3000
-0.0500 (-3.70%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.3500
Open1.3500
Bid0.0000 x 4000
Ask0.0000 x 900
Day's Range1.2600 - 1.3700
52 Week Range1.1000 - 25.4000
Volume80,532
Avg. Volume340,495
Market Cap8.96M
Beta (3Y Monthly)1.97
PE Ratio (TTM)N/A
EPS (TTM)-14.5540
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire

    GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch™ Wearable Device in Preclinical Study

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses their proprietary h-Patch™ technology, announced today positive topline results from a preclinical pharmacokinetic (PK) study. The study evaluated subcutaneous infusion of a GLP-1 analogue via its proprietary h-Patch™ wearable drug delivery device. Valeritas’ h-Patch™ is a drug delivery technology that can facilitate the simple and effective subcutaneous delivery of injectable medicines to patients across a broad range of therapeutic areas.

  • GlobeNewswire

    Valeritas Presents Positive h-Patch™ Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced positive data from its preclinical pharmacokinetic (PK) study of apomorphine (APO) subcutaneous infusion was presented today at Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia (Dementia 2019) in Rome, Italy. In the poster presentation titled “Preclinical Pilot Study Result of 24-Hour Apomorphine Subcutaneous Infusion Delivered via the h-Patch™ Wearable Device,” the data demonstrated rapid absorption and distribution of 400ul of a 25mg/ml APO solution with the h-Patch™ technology. APO was detected in plasma within two hours of the start of infusion, and still detectable 24 hours after completion of h-Patch™ infusion, or 48 hours in total.

  • GlobeNewswire

    Valeritas Announces Poster Presentation of Preclinical h-Patch™ Cannabidiol (CBD) Study at the American Epilepsy Society's Annual Meeting

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today a poster presentation at the American Epilepsy Society's Annual Meeting held in Baltimore, Maryland, on December 6-10, 2019. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device. The company believes this study represents the first report of CBD delivered via subcutaneous infusion in any preclinical model.

  • GlobeNewswire

    Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the World Congress of Neurology (WCN 2019)

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today a poster presentation at the 24th World Congress of Neurology held in Dubai, UAE, on October 27-31, 2019. On August 5th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of continuous subcutaneous infusion of apomorphine (Apo) delivered via its proprietary h-Patch™ wearable drug delivery device.

  • GlobeNewswire

    Valeritas Hosts Educational Symposium and Participates in the Metabolic & Endocrine Disease Summit (MEDS) East

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today it will be hosting an educational symposium and participating at the Metabolic & Endocrine Disease Summit (MEDS) in Orlando, Florida. On October 4, Valeritas will be hosting an educational breakfast where attendees will be given an opportunity to learn and broaden their knowledge and understanding of V-Go and how its proper use can lead to lower insulin dose requirements and lower diabetes-related medication cost while lowering average blood sugar levels, as measured by A1c. “We are very excited to participate in the 2019 MED East Summit, as it is designed to enhance the knowledge base of those healthcare professionals who diagnose, manage, and treat metabolic and endocrine diseases,” said John Timberlake, President and Chief Executive Officer of Valeritas.

  • GlobeNewswire

    Valeritas Reduces its Long-Term Debt Obligation Nearly 60% by Exchanging $25.0 Million of Debt for Series B Convertible Preferred Stock

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today the restructuring of a substantial portion of its outstanding long-term debt, reducing the total debt balance by an aggregate of $25.0 million. Under the terms of the debt restructuring, $25.0 million of Valeritas senior secured long-term debt held by CR Group L.P. (CRG) affiliated funds and another creditor was exchanged for newly created Valeritas Series B Convertible Preferred Stock, the terms of which are disclosed in a Form 8-K to be filed with the SEC. The debt exchange reduces the outstanding balance of senior secured debt to approximately $17.0 million.

  • Medtronic's All Business Lines Grow Despite Cost Concerns
    Zacks

    Medtronic's All Business Lines Grow Despite Cost Concerns

    Within Diabetes group, Medtronic (MDT) is seeing a strong adoption of the Guardian Connect Smart CGM system.

  • Boston Scientific (BSX) Upbeat on Results of EVOLVE Study
    Zacks

    Boston Scientific (BSX) Upbeat on Results of EVOLVE Study

    Boston Scientific (BSX) is hopeful about robust data outcome on DAPT study as the therapy duration might prove to be a superior treatment option.

  • Haemonetics Grows on Strong Plasma, Hemostasis Management
    Zacks

    Haemonetics Grows on Strong Plasma, Hemostasis Management

    Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.

  • NuVasive Announces Innovations in Robotics Spine Surgery Line
    Zacks

    NuVasive Announces Innovations in Robotics Spine Surgery Line

    NuVasive (NUVA) aims to speed up the adoption of less invasive spine surgery through robotics.

  • GlobeNewswire

    Valeritas Announces Participation on “The Cutting Edge of Cannabinoid Science” Panel at the CBD Expo EAST Conference

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today that Dr. Jessica Barnes, consultant to the company, will be a panelist at CBD Expo EAST 2019 being held November 15-16, 2019, at the Hilton Orlando in Orlando, Florida. The past year’s breakthroughs in CBD research include medication interactions, epilepsy, neuroscience, dermatological applications, mental health disorders, addiction/relapse, and biochemistry. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device.

  • GlobeNewswire

    Valeritas Presents Positive h-Patch™ CBD Study Data at CannMed Conference

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced positive data from its preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion was presented today at the CannMed Conference in Pasadena, California. The company believes this study represents the first report of CBD delivered via subcutaneous infusion in any preclinical model. In the poster presentation titled “Pharmacokinetic Study of Subcutaneous Infusion of Cannabinoid (CBD) Isolate in Dogs via the h-Patch™ Wearable Device,” the data demonstrated rapid and robust absorption and distribution of 40mg of CBD delivered over 24 hours with the h-Patch™ technology.

  • GlobeNewswire

    Valeritas Announces Presentation of Preclinical h-Patch™ CBD Study at CannMed Conference

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today data from its preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion delivered via its h-Patch™ wearable drug delivery device have been accepted for a poster presentation at the annual CannMed Conference in Pasadena, CA, on September 23-24, 2019. Pharmacokinetic Study of Subcutaneous Infusion of Cannabinoid (CBD) Isolate in Dogs via the   h-Patch™ Wearable Device. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device.

  • GlobeNewswire

    Valeritas Announces Poster Presentation of Preclinical h-Patch™ Apomorphine Study at the Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today a poster presentation at the Global Experts Meeting on Frontiers in Alzheimer’s Disease & Dementia held in Rome, Italy, on October 14-16, 2019. On August 5th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of continuous subcutaneous infusion of apomorphine (Apo) delivered via its proprietary h-Patch™ wearable drug delivery device. The wearable h-Patch™ represents a patient-friendly subcutaneous delivery mechanism for Apo providing the benefits of a full 24-hour infusion of low dose Apo to eliminate “off” periods and improve motor status without tolerability issues seen with subcutaneous injections.

  • Benzinga

    A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019

    This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. Sintx Technologies (NASDAQ: SINT ) shares ...

  • GlobeNewswire

    Valeritas Presents Positive CBD h-Patch™ Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today positive data from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion was presented at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit in Boston, Massachusetts. Data presented at the Summit showed rapid and robust absorption and distribution of 40mg CBD delivered over 24 hours with the h-Patch™ technology. “We are very excited by the data from this PK study and the potential our h-Patch™ technology has in providing peak plasma levels equivalent to oral administration despite delivering only a fraction of the amount of CBD,” said John Timberlake, President and Chief Executive Officer of Valeritas.

  • GNC Holdings Inks Retail Partnership Deal to Grow in Brazil
    Zacks

    GNC Holdings Inks Retail Partnership Deal to Grow in Brazil

    We consider this corporate deal in Brazil to be a strategic fit for GNC Holdings (GNC), which currently pulls out all the stops to fortify its global footprint.

  • Innovation Aids Genomic Health, Merger Procedure on Track
    Zacks

    Innovation Aids Genomic Health, Merger Procedure on Track

    Genomic Health (GHDX) is on course to realize its impending merger with cancer diagnostics major Exact Sciences, which will integrate brands like Cologuard and OncotypeDX.

  • Insulet (PODD) Scales 52-Week High: What's Driving the Stock?
    Zacks

    Insulet (PODD) Scales 52-Week High: What's Driving the Stock?

    Insulet (PODD) has various favorable factors to maintain the current high.

  • GlobeNewswire

    Valeritas Announces Oral Presentation of Preclinical h-Patch™ CBD Study at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of the V-Go® Wearable Insulin Delivery device, which uses its proprietary h-Patch™ technology, announced today an oral presentation to be given at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit held in Boston, MA, on September 10-12, 2019. On July 30th, Valeritas announced positive results from a preclinical pharmacokinetic (PK) study of cannabidiol (CBD) subcutaneous infusion with two dosing regimens delivered via its proprietary h-Patch™ wearable drug delivery device.

  • Thomson Reuters StreetEvents

    Edited Transcript of VLRX earnings conference call or presentation 8-Aug-19 8:30pm GMT

    Q2 2019 Valeritas Holdings Inc Earnings Call

  • GlobeNewswire

    Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that the Compensation Committee of Valeritas’ Board of Directors granted stock options to purchase an aggregate of 1,665 shares of Valeritas’ common stock to 4 newly-hired employees, with a grant date of August 28, 2019, pursuant to the Valeritas Holdings, Inc. 2018 Inducement Plan that was previously disclosed. The stock options were granted as inducements material to the new employees entering into employment with Valeritas in accordance with NASDAQ Listing Rule 5635(c)(4).

  • GlobeNewswire

    Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas’ V-Go® Meets Primary A1c Endpoint

    Valeritas Holdings, Inc. (VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple, all-in-one, wearable insulin delivery option for patients with diabetes, today announced that a randomized controlled trial comparing the delivery of U-100 Regular Human Insulin (RHI) by V-Go versus delivery of Rapid Acting Insulin (RAI) by V-Go in patients with type 2 diabetes has met the primary A1c (blood sugar levels) endpoint.

  • Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates

    Valeritas Holdings, Inc. (VLRX) delivered earnings and revenue surprises of 5.86% and 0.19%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Valeritas Announces Second Quarter 2019 Financial Results

    BRIDGEWATER, N.J., Aug. 08, 2019 -- Valeritas Holdings, Inc. (NASDAQ: VLRX), a medical technology company and maker of V-Go® Wearable Insulin Delivery device, a simple,.